NCT05570955Active, not recruiting
Deucravacitinib Adherence Study
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
Psoriasis patients are very poorly adherent to topical treatment. If adherence issues are ignored, poor adherence may limit the real-world efficacy of deucravacitinib, too. Forty psoriasis patients recruited from Wake Forest Baptist Health Dermatology Clinic will be enrolled. Twenty will be randomized to a reporting intervention designed to promote better adherence and the remaining 20 patients will serve as controls who will not receive a reporting intervention. Through qualitative interviews of the 40 patients recruited, we plan to study the behaviors of the most adherent patients to better understand specific beliefs and behaviors of adherent patients and to identify practical, modifiable factors that can improve adherence. We will also compare treatment outcomes and efficacy of deucravacitinib between the most and least adherence patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 22 Sept 2022
- Start date
- 24 Jul 2023
- Primary completion date
- Nov 2026
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Psoriasis
- NCT number
- NCT05570955
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 24 Jul 2023 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with active substance or alcohol abuse disorder; or history of substance/alcohol abuse disorder within 6 months prior to study enrollment.
- Patients that are taking concomitant biologics, systemics for the treatment of psoriasis and/or phototherapy.
Other illness
- Patients with severe or unstable comorbid conditions.
- Patients with active malignancy or malignancy in past 5 years (not including appropriately treated cutaneous basal and cutaneous-limited squamous cell carcinomas).
- Patients with any other skin condition that prohibit or confound the ability of the investigator to interpret skin findings.
- History of, or active, severe depression and/or suicidality.
- Patients with active or latent tuberculosis as determined by quant-TB baseline testing
Age
- Patients under 18 years of age.
Other
- Patients without a diagnosis of moderate-to-severe plaque psoriasis.
- Patients who are pregnant or breastfeeding.
Who the study is looking for
- Patients with moderate-to-severe plaque psoriasis. Standard criteria for moderate-to-severe plaque psoriasis will be used (BSA greater than or equal to 3% or face/palm/sole/genital involvement or severe effect on Quality of Life).
- Subject must be 18 years of age or older.
- Subject must have a working knowledge of English.
- Approved birth control methods required for females of childbearing potential.
- Baseline TB test.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wake Forest University Health Sciences Department of Dermatology Coordinator of this site? Confirm its status | Winston-Salem | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.